PCI 3.06.26

Current Edition

Current Features

Subsection - Neurodegenerative Diseases

From Depression to Deep-Learning: Leveraging iPSC and AI Platforms for Evidence-Based Depression Treatment

Continue reading

Subsection - Oncology

Essential DMPK Strategies for IND Success

Continue reading

Subsection - Cell and Gene Therapy

When the Gene Editing Guide is the Drug

Continue reading

Upcoming Events

CPHI 2027
AI in Drug Discovery
Auto Draft
Auto Draft
Elrig
Auto Draft
DDL 2026
Biotechnology Show 13.02.26

Advertisement

Advertisement

A&M Stabtest April 26

Advertisement

Biopharma Group – 19th March 2025

Advertisement

Micron View

Advertisement

Bachem skyscraper

Fluid Management as a Strategic Enabler in Biopharmaceutical Manufacturing

In cell and gene therapy manufacturing, a contamination event during fill-finish doesn’t just cost product; it can cost months of patient wait time. The fluid path that carried the material there is rarely where post-mortems start,
but it’s where it should. Fluid management has long been treated as an operational support function, necessary but not strategic. That framing is changing, and for good reason.

This shift to a strategic role is advantageous in the context f aggressive investment in advanced biologics, increasing regulatory scrutiny and a growing emphasis on speed-to-market without compromising control or quality. In this environment, integrated fluid management systems, whether standard, configurable or engineered-to-order, play a pivotal role, helping manufacturers bridge from development and commercialisation
while enabling more robust, flexible operations.

The Evolving Demands of Bioprocessing Operations

From monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs) to cell and gene therapies, each therapeutic modality introduces unique processing requirements. Biologics can have varying sensitivity to shear forces, temperature fluctuations and material interactions, which place new demands on fluid handling systems. At the same time, manufacturers need to scale processes more quickly and efficiently.

The traditional bioproduction model, where fluid management approaches are adapted or re-engineered at each
stage of scale-up, is no longer practical or sustainable in such a highly competitive environment. Instead, there is a growing need for systems that speed transition from development to GMP manufacturing, maintaining process integrity at every step and meeting the specific needs of different molecules and workflows.

Integrated fluid management systems are designed to address these challenges by bringing together peristaltic
pumps, single-use assemblies, systems, connectors and control elements into cohesive platforms. The result is not only greater operational efficiency and scalability but also improved process understanding and control.

Advertisement

Richter: Wed 23 October 2024, 09:03

Advertisement

Aseptic Tech

Advertisement

Steribar – 12.05.2025

Advertisement

PharmExcel

Advertisement

Polypure hompage

Advertisement

Gen Xpro

Advertisement

Alphinity

Advertisement

Crown Bioscience

Advertisement

Shimadzu

Advertisement

CPC

Thanks for reading International Biopharmaceutical Industry.

Fill the from to continue reading.